Education
About Us
Working with TipRanks
Follow Us
PureTech Health (PRTC)
NASDAQ:PRTC
Top Page
PureTech Health
(NASDAQ:PRTC)
Select Model
Select Model
Rating:55Neutral
Price Target:
$16.00
▲(0.00% Upside)
PureTech Health's overall stock score reflects a mixed financial performance with a strong balance sheet but operational inefficiencies. Technical analysis indicates bearish momentum, while valuation suggests potential undervaluation. The earnings call provided a balanced outlook with strong cash reserves but highlighted challenges in external financing and leadership transitions.
Positive Factors
Strong Cash Position
A robust cash position enhances financial stability, allowing for strategic investments and operational resilience, supporting long-term growth.
Progress in Core Founded Entities
Advancements in core entities indicate strong R&D capabilities and potential for future revenue streams, reinforcing competitive positioning.
Successful Financing of Seaport Therapeutics
Successful financing rounds reflect investor confidence and provide capital to advance key projects, supporting long-term strategic goals.
Negative Factors
Dependence on External Financing
Reliance on external funding can lead to financial uncertainty and potential dilution, impacting long-term financial health and shareholder value.
Leadership Transition
Leadership changes can disrupt strategic direction and execution, potentially affecting company performance and investor confidence over time.
Operational Inefficiencies
Operational inefficiencies can hinder profitability and growth, requiring strategic adjustments to improve long-term operational performance.
PureTech Health (PRTC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$403.97M
Dividend YieldN/A
Average Volume (3M)4.02K
Price to Earnings (P/E)9.4
Beta (1Y)0.49
Revenue Growth1268.81%
EPS GrowthN/A
CountryUS
Employees80
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.90
Shares Outstanding24,168,404
10 Day Avg. Volume1,390
30 Day Avg. Volume4,023
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)1.20
Price to Sales (P/S)103.10
P/FCF Ratio-3.70
Enterprise Value/Market Cap0.26
Enterprise Value/Revenue18.12
Enterprise Value/Gross Profit5.35
Enterprise Value/Ebitda1.91
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
PureTech Health Business Overview & Revenue Model
Company DescriptionPureTech Health (PRTC) is a biotechnology company that focuses on discovering, developing, and commercializing innovative treatments for various health conditions. The company operates primarily in the biopharmaceutical sector, targeting areas such as neurology, immunology, and oncology. PureTech's business model centers around advancing its proprietary technologies and platforms, which include a range of therapeutics and drug candidates designed to address unmet medical needs.
How the Company Makes MoneyPureTech Health generates revenue through several key streams, including licensing agreements, collaborations, and equity stakes in its pipeline companies. The company often partners with larger pharmaceutical firms to co-develop its products, which provides upfront payments and milestone payments tied to the success of the development process. Additionally, PureTech may earn royalties on sales generated from products developed through these collaborations. Its significant investments in its subsidiaries and joint ventures also contribute to potential future revenues as these entities progress towards commercialization.
PureTech Health Earnings Call Summary
Earnings Call Date:Aug 28, 2025
(Q2-2025)
| % Change Since: |
Next Earnings Date:Apr 23, 2026
Earnings Call Sentiment Neutral
The earnings call highlighted PureTech's strong cash position and operational efficiency, progress in core founded entities, and strategic financing with promising valuation for Seaport Therapeutics. However, there are challenges with the need for ongoing external financing for core entities and leadership transitions. The overall sentiment is balanced with strong positive aspects but also significant challenges.Q2-2025 Updates
Positive Updates
Strong Cash Position and Operational Efficiency
PureTech ended the half year with just under $320 million in cash, cash equivalents, and short-term investments. Operating expenses reduced from $66.7 million in the same period last year to just under $50 million, demonstrating efficient operations.
Successful Financing and Valuation of Seaport Therapeutics
Seaport Therapeutics, a core founded entity of PureTech, raised over $325 million with a $733 million post-money valuation during its Series B round.
Progress in Core Founded Entities
Significant progress in Celea Therapeutics, Gallop Oncology, and Seaport Therapeutics with promising data in IPF and cancer treatments. Notable FDA designations for LYT-200 in Gallop Oncology.
Significant Potential from Cobenfy Royalties
PureTech holds a 2% royalty on Cobenfy sales above $2 billion annually, with potential milestones projecting around $300 million in value based on analyst forecasts.
Negative Updates
Dependence on External Financing for Core Entities
Celea Therapeutics and Gallop Oncology require external funding to advance their programs, leaving some uncertainty about future financing structures and potential dilution.
Leadership Transition and Interim Management
PureTech is currently under interim leadership with Robert Lyne as Interim CEO, following recent management changes and the departure of the previous Chair.
Company Guidance
During the PureTech Health 2025 Half Year Earnings Webcast, the company provided guidance focusing on three key strategic pillars: developing new treatments with patient-centered urgency, strengthening engagement with U.K. capital markets, and maintaining a disciplined capital allocation approach. PureTech highlighted its promising lead program, deupirfenidone (LYT-100), significant progress in clinical trials, and the potential to deliver long-term value for patients and shareholders. The company also discussed its hub-and-spoke model, exemplified by the success of Karuna Therapeutics, which involved an $18.5 million initial investment leading to a significant financial return. Additionally, PureTech announced plans to appoint up to two new nonexecutive directors to strengthen its board with U.K. capital markets expertise. The interim CEO, Robert Lyne, emphasized their focus on operational discipline and leveraging external capital to fund new entities like Seaport Therapeutics, Gallop Oncology, and Celea Therapeutics, aiming to extend the operational runway well into 2028 with a strong cash position of just under $320 million.PureTech Health Financial Statement Overview
Summary
PureTech Health shows a mixed financial outlook. The balance sheet is strong with low leverage, but income and cash flow statements highlight operational inefficiencies. The transition to positive net income in 2024 is promising, yet sustained profitability remains uncertain.Income Statement
PureTech Health has shown inconsistent revenue growth with a significant increase from 2023 to 2024. However, the company is operating at a loss, with negative EBIT and EBITDA margins indicating operational challenges. Although net profit margin turned positive in 2024, this has been volatile over the years.40
Negative
Balance Sheet
The company's balance sheet shows a strong equity ratio and low debt-to-equity ratio, suggesting good financial stability. However, the decrease in stockholders' equity over recent years could be a concern for long-term sustainability. Return on Equity turned positive in 2024, but this metric has been inconsistent historically.55
Neutral
Cash Flow
Cash flow analysis reveals negative free cash flow, although the company has managed a positive investing cash flow, likely from asset sales or investments. The operating cash flow to net income ratio is negative, suggesting that core operations are not generating sufficient cash.60
Neutral
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.88M | 4.83M | 3.33M | 2.09M | 9.98M | 8.34M |
| Gross Profit | 19.91M | 1.26M | -1.60M | -136.81M | -100.49M | 8.34M |
| EBITDA | 55.73M | 37.38M | -11.63M | -188.91M | 26.70M | 62.69M |
| Net Income | 50.68M | 53.51M | -65.70M | -50.35M | -60.56M | 5.99M |
Balance Sheet | ||||||
| Total Assets | 553.24M | 602.63M | 693.97M | 702.65M | 946.01M | 989.99M |
| Cash, Cash Equivalents and Short-Term Investments | 321.55M | 367.31M | 327.14M | 350.10M | 465.71M | 403.88M |
| Total Debt | 20.92M | 22.36M | 25.34M | 46.87M | 52.75M | 76.62M |
| Total Liabilities | 184.22M | 194.70M | 235.74M | 155.06M | 361.86M | 336.45M |
| Stockholders Equity | 375.98M | 414.71M | 464.07M | 542.22M | 593.51M | 669.75M |
Cash Flow | ||||||
| Free Cash Flow | -100.31M | -134.38M | -106.16M | -180.97M | -163.94M | -137.25M |
| Operating Cash Flow | -100.30M | -134.37M | -105.92M | -178.79M | -158.27M | -131.83M |
| Investing Cash Flow | 31.89M | 240.89M | 68.99M | -107.22M | 197.38M | 364.48M |
| Financing Cash Flow | 18.51M | -16.96M | 78.14M | -29.83M | 22.73M | 38.87M |
PureTech Health Technical Analysis
Negative
16.00
Price Trends
17.26
Negative
17.53
Negative
17.64
Negative
Market Momentum
-0.44
Positive
42.26
Neutral
32.11
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PRTC, the sentiment is Negative. The current price of 16 is below the 20-day moving average (MA) of 16.56, below the 50-day MA of 17.26, and below the 200-day MA of 17.64, indicating a bearish trend. The MACD of -0.44 indicates Positive momentum. The RSI at 42.26 is Neutral, neither overbought nor oversold. The STOCH value of 32.11 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PRTC.
PureTech Health Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $403.97M | 9.39 | 14.55% | ― | 1268.81% | ― | |
53 Neutral | $627.91M | ― | -45.38% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | $364.61M | ― | -60.52% | ― | 407.86% | 30.35% | |
47 Neutral | $536.39M | ― | ― | ― | 6.35% | 39.57% | |
44 Neutral | $719.27M | ― | -43.15% | ― | ― | -2.74% | |
43 Neutral | $464.65M | ― | -55.68% | ― | -33.09% | 3.38% |
* Healthcare Sector Average
PRTC
PureTech Health
16.70
-5.29
-24.06%
ATXS
Astria Therapeutics
12.65
2.28
21.99%
AUTL
Autolus Therapeutics
1.41
-1.85
-56.75%
ADCT
ADC Therapeutics
4.30
1.98
85.34%
FDMT
4D Molecular Therapeutics
11.66
4.07
53.62%
ABSI
AbSci
3.17
0.02
0.63%
PureTech Health Corporate Events
PureTech Health Reports Strong Progress and Financial Stability
Aug 29, 2025
PureTech Health plc is a biotherapeutics company operating in the healthcare sector, known for its innovative hub-and-spoke R&D model that transforms scientific innovation into value by advancing therapeutic candidates through its Founded Entities. In its latest half-yearly report, PureTech Health highlighted significant progress in advancing its diversified portfolio, particularly with the launch of Celea Therapeutics and the continued development of Gallop Oncology. The company reported a strong financial position with cash reserves of $319.6 million, providing an operational runway into 2028, and emphasized its commitment to capital-efficient innovation and shareholder value creation. Key financial metrics include reduced operating expenses of $49.8 million compared to the previous year, and strategic moves such as the divestment of equity holdings in Vor Biopharma. Looking forward, PureTech aims to maintain its disciplined capital allocation strategy, focusing on advancing promising programs and strengthening its engagement with UK capital markets, while anticipating a reduction in operational expenses as responsibilities transition to Founded Entities.
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.